BCL2 and cancer: Recently, EVs derived from cancer cells were shown to reduce the apoptosis rate via upregulation of BCL2 in other cancer cells (64), and tumor-derived EVs containing extracellular matrix molecules induced mutations in PIK3CA, which promoted proliferation and invasion in breast cancer (65).